OTCMKTS:GNMSF - Genmab As Stock Price, Price Target & More

$197.51 -11.99 (-5.72 %)
(As of 04/25/2018 10:20 AM ET)
Previous Close$209.50
Today's Range$197.51 - $197.51
52-Week Range$163.00 - $239.75
Volume100 shs
Average Volume622 shs
Market Capitalization$12.84 billion
P/E Ratio76.46
Dividend YieldN/A
Beta0.55

About Genmab As (OTCMKTS:GNMSF)

Genmab As logoGenmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM). Its products under development include Ofatumumab to treat CLL and follicular lymphoma; Ofatumumab (OMB157) for relapsing remitting multiple sclerosis; and Daratumumab to treat MM, Non-Hodgkin's lymphoma, and solid tumors, as well as natural killer/T-cell lymphoma, nasal type. The company’s products under development also comprise Tisotumab vedotin for treating solid cancers; HuMax-AXL-ADC for solid cancers; Teprotumumab for the treatment of Graves' orbitopathy; AMG 714 for celiac disease; ADCT-301 (HuMax-TAC-ADC) to treat lymphoma and acute myeloid leukemia (AML) or acute lymphoblastic leukemia; JNJ-61186372 for non-small-cell lung cancer; and NJ-63709178 for the treatment of AML. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company was founded in 1999 and is based in Copenhagen, Denmark.

Receive GNMSF News and Ratings via Email

Sign-up to receive the latest news and ratings for GNMSF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:GNMSF
CUSIPN/A
Phone45-7020-2728

Debt

Debt-to-Equity RatioN/A
Current Ratio18.53%
Quick Ratio18.53%

Price-To-Earnings

Trailing P/E Ratio76.46
Forward P/E Ratio75.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$359.30 million
Price / Sales33.69
Cash Flow$2.5828 per share
Price / Cash76.47
Book Value$15.57 per share
Price / Book12.69

Profitability

EPS (Most Recent Fiscal Year)$2.86
Net Income$167.62 million
Net Margins46.66%
Return on Equity20.08%
Return on Assets18.61%

Miscellaneous

Employees205
Outstanding Shares61,280,000

How to Become a New Pot Stock Millionaire

Genmab As (OTCMKTS:GNMSF) Frequently Asked Questions

What is Genmab As' stock symbol?

Genmab As trades on the OTCMKTS under the ticker symbol "GNMSF."

How were Genmab As' earnings last quarter?

Genmab As (OTCMKTS:GNMSF) released its quarterly earnings results on Wednesday, November, 5th. The company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.45 by $0.02. The business earned $45.65 million during the quarter, compared to analyst estimates of $53.94 million. Genmab As had a return on equity of 20.08% and a net margin of 46.66%. View Genmab As' Earnings History.

When is Genmab As' next earnings date?

Genmab As is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Genmab As.

Who are some of Genmab As' key competitors?

Has Genmab As been receiving favorable news coverage?

Press coverage about GNMSF stock has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Genmab As earned a news impact score of 0.10 on Accern's scale. They also gave media headlines about the company an impact score of 44.95 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Genmab As?

Shares of GNMSF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genmab As' stock price today?

One share of GNMSF stock can currently be purchased for approximately $197.51.

How big of a company is Genmab As?

Genmab As has a market capitalization of $12.84 billion and generates $359.30 million in revenue each year. The company earns $167.62 million in net income (profit) each year or $2.86 on an earnings per share basis. Genmab As employs 205 workers across the globe.

How can I contact Genmab As?

Genmab As' mailing address is BREDGADE 34E, COPENHAGEN G7, . The company can be reached via phone at 45-7020-2728 or via email at [email protected]


MarketBeat Community Rating for Genmab As (GNMSF)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  68 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  187
MarketBeat's community ratings are surveys of what our community members think about Genmab As and other stocks. Vote "Outperform" if you believe GNMSF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMSF will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genmab As (OTCMKTS:GNMSF) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for Genmab As in the last 12 months. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Genmab As (OTCMKTS:GNMSF) Consensus Price Target History

Price Target History for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS:GNMSF) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
10/6/2017JPMorgan ChaseDowngradeOverweight -> NeutralView Rating Details
4/4/2017Deutsche BankDowngradeBuy -> HoldView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Genmab As (OTCMKTS:GNMSF) Earnings History and Estimates Chart

Earnings by Quarter for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS:GNMSF) Earnings Estimates

2018 EPS Consensus Estimate: $3.70
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.72$0.72$0.72
Q2 20181$0.13$0.13$0.13
Q3 20181$2.12$2.12$2.12
Q4 20181$0.73$0.73$0.73

Genmab As (OTCMKTS GNMSF) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018        
11/8/2017Q3 2017($0.01)$51.08 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.73$114.26 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.04$35.19 million$35.93 millionViewN/AView Earnings Details
3/28/2017Q4 2016$1.98$134.64 millionViewN/AView Earnings Details
11/2/2016Q3 2016$0.46$54.70 millionViewN/AView Earnings Details
8/9/2016Q2 2016$0.24$0.41$49.68 million$53.72 millionViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.03)$10.31 million$25.15 millionViewN/AView Earnings Details
2/17/2016Q4 2015$0.95$84.32 millionViewN/AView Earnings Details
11/3/2015Q3 2015$0.34$41.41 millionViewN/AView Earnings Details
8/11/2015Q2 2015$0.44$0.04$47.57 million$25.76 millionViewN/AView Earnings Details
5/12/2015Q1 2015$0.55$16.19 millionViewN/AView Earnings Details
11/5/2014Q3 2014$0.45$0.47$53.94 million$45.65 millionViewN/AView Earnings Details
8/13/2014Q2 2014($0.06)($0.08)$26.02 million$20.79 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.09)$0.33$21.18 million$46.08 millionViewN/AView Earnings Details
11/6/2013Q3 2013($0.01)$0.02$25.52 million$27.12 millionViewN/AView Earnings Details
8/14/2013Q2 2013($0.01)($0.09)$24.45 million$24.54 millionViewN/AView Earnings Details
5/7/2013Q1 2013$0.11$28.09 millionViewN/AView Earnings Details
11/7/2012Q3 2012($0.17)($0.17)ViewN/AView Earnings Details
8/15/2012Q2 2012($0.32)$0.03ViewN/AView Earnings Details
5/15/2012Q1 2012($0.25)($0.23)ViewN/AView Earnings Details
11/2/2011Q3 2011($0.04)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.43)ViewN/AView Earnings Details
11/22/2010Q3 2010$0.48ViewN/AView Earnings Details
8/17/2010Q2 2010($0.46)($0.30)ViewN/AView Earnings Details
5/11/2010Q1 2010($0.77)($0.47)ViewN/AView Earnings Details
11/10/2009Q3 2009($1.17)($0.44)ViewN/AView Earnings Details
8/18/2009Q2 2009($1.18)($0.54)ViewN/AView Earnings Details
5/12/2009Q1 2009($1.04)($0.79)ViewN/AView Earnings Details
8/27/2008Q2 2008($1.38)ViewN/AView Earnings Details
5/28/2008Q1 2008($0.95)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Genmab As (OTCMKTS:GNMSF) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Genmab As (OTCMKTS GNMSF) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 0.09%
Insider Trading History for Genmab As (OTCMKTS:GNMSF)

Genmab As (OTCMKTS GNMSF) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Genmab As (OTCMKTS GNMSF) News Headlines

Source:
DateHeadline
Analyzing Genmab As (GNMSF) and Celyad (CYAD)Analyzing Genmab As (GNMSF) and Celyad (CYAD)
www.americanbankingnews.com - April 24 at 7:24 PM
Head-To-Head Analysis: Genmab As (GNMSF) & Its PeersHead-To-Head Analysis: Genmab As (GNMSF) & Its Peers
www.americanbankingnews.com - April 24 at 7:48 AM
Zacks Investment Research Upgrades Genmab As (GNMSF) to HoldZacks Investment Research Upgrades Genmab As (GNMSF) to Hold
www.americanbankingnews.com - April 19 at 12:28 AM
Genmab As (GNMSF) Upgraded to "Hold" by ValuEngineGenmab As (GNMSF) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 5 at 1:11 PM
Analyzing Akebia Therapeutics (AKBA) and Genmab As (GNMSF)Analyzing Akebia Therapeutics (AKBA) and Genmab As (GNMSF)
www.americanbankingnews.com - April 3 at 3:09 AM
Genmab As (GNMSF) Rating Increased to Hold at Zacks Investment ResearchGenmab As (GNMSF) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 31 at 11:09 AM
Genmab (GNMSF) Presents At Deutsche Banks Depositary Receipts Virtual Investor Conference - SlideshowGenmab (GNMSF) Presents At Deutsche Bank's Depositary Receipts Virtual Investor Conference - Slideshow
seekingalpha.com - March 26 at 3:53 PM
Jefferies Group Comments on Genmab As FY2018 Earnings (GNMSF)Jefferies Group Comments on Genmab As' FY2018 Earnings (GNMSF)
www.americanbankingnews.com - February 26 at 6:44 AM
Genmab As (GNMSF) Expected to Earn Q1 2018 Earnings of $0.72 Per ShareGenmab As (GNMSF) Expected to Earn Q1 2018 Earnings of $0.72 Per Share
www.americanbankingnews.com - February 23 at 8:06 AM
Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF)Q4 2017 Earnings Forecast for Genmab As Issued By Jefferies Group (GNMSF)
www.americanbankingnews.com - February 7 at 8:18 AM
Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)Genmab Announces 2017 Net Sales Figures for DARZALEX® (Daratumumab)
finance.yahoo.com - January 23 at 8:50 AM
U.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple MyelomaU.S. FDA Grants Priority Review for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - January 19 at 5:33 PM
Genmab As (GNMSF) Rating Lowered to Sell at Zacks Investment ResearchGenmab As (GNMSF) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 9 at 11:54 PM
Analysts Issue Forecasts for Genmab As FY2018 Earnings (GNMSF)Analysts Issue Forecasts for Genmab As' FY2018 Earnings (GNMSF)
www.americanbankingnews.com - January 8 at 12:06 PM
ETFs with exposure to Genmab A/S : December 27, 2017ETFs with exposure to Genmab A/S : December 27, 2017
finance.yahoo.com - December 28 at 6:10 AM
Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2017 By the Numbers : December 26, 2017
finance.yahoo.com - December 26 at 9:16 AM
After Soaring 3,000% in 5 Years, Genmab Tests Stock-Market HabitAfter Soaring 3,000% in 5 Years, Genmab Tests Stock-Market Habit
finance.yahoo.com - December 18 at 5:04 PM
Genmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial GuidanceGenmab Achieves USD 20 Million Milestone in Daratumumab Collaboration with Janssen and Updates Financial Guidance
finance.yahoo.com - November 29 at 5:24 PM
Genmab A/S (GNMSF) Downgraded by Zacks Investment ResearchGenmab A/S (GNMSF) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 26 at 3:34 PM
Genmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple MyelomaGenmab Announces European Regulatory Submission for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - November 21 at 7:08 PM
Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple MyelomaGenmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - November 21 at 7:08 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : November 16, 2017
finance.yahoo.com - November 16 at 2:48 PM
Major Shareholder AnnouncementMajor Shareholder Announcement
finance.yahoo.com - November 11 at 7:23 AM
Genmab Announces Financial Results for the First Nine Months of 2017Genmab Announces Financial Results for the First Nine Months of 2017
finance.yahoo.com - November 9 at 6:12 AM
Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017Genmab A/S – Value Analysis (US OTC:GNMSF) : November 1, 2017
finance.yahoo.com - November 1 at 9:07 PM
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 31, 2017
finance.yahoo.com - October 31 at 8:33 PM
Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017Genmab Announces Additional Information Concerning Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
finance.yahoo.com - October 25 at 2:33 AM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : October 18, 2017
finance.yahoo.com - October 19 at 12:08 AM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2017
finance.yahoo.com - October 17 at 7:52 PM
Seattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registrationSeattle Genetics initiates mid-stage of tisotumab vedotin in cervical cancer, positive results may support registration
seekingalpha.com - October 10 at 9:53 PM
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical CancerGenmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
finance.yahoo.com - October 10 at 4:49 PM
Genmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & CoGenmab A/S (GNMSF) Rating Lowered to Neutral at J P Morgan Chase & Co
www.americanbankingnews.com - October 7 at 3:36 PM
Genmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in JapanGenmab Announces Approval of DARZALEX® (daratumumab) for Relapsed or Refractory Multiple Myeloma in Japan
finance.yahoo.com - October 2 at 1:56 PM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : September 18, 2017
finance.yahoo.com - September 18 at 6:43 PM
Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017Genmab A/S :GNMSF-US: Earnings Analysis: Q2, 2017 By the Numbers : September 12, 2017
finance.yahoo.com - September 12 at 7:58 PM
Seattle Genetics and Genmab team up to develop ADC tisotumab vedotinSeattle Genetics and Genmab team up to develop ADC tisotumab vedotin
seekingalpha.com - August 30 at 9:33 PM
J&Js Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP aloneJ&J's Darzalex extends progression-free survival in late-state multiple myeloma study over Velcade/MP alone
seekingalpha.com - August 25 at 6:20 AM
Genmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple MyelomaGenmab Announces Positive Topline Results in Phase III ALCYONE Study of Daratumumab in Front Line Multiple Myeloma
finance.yahoo.com - August 25 at 6:20 AM
Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017Genmab A/S – Value Analysis (US OTC:GNMSF) : August 21, 2017
finance.yahoo.com - August 23 at 7:38 AM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 21, 2017
finance.yahoo.com - August 21 at 6:32 PM
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 10, 2017
finance.yahoo.com - August 11 at 12:47 AM
Genmabs (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 7:18 PM
Genmab Announces Financial Results for the First Half of 2017Genmab Announces Financial Results for the First Half of 2017
finance.yahoo.com - August 9 at 7:18 PM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2017
finance.yahoo.com - July 18 at 8:51 PM
Genmabs (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q1 2017 Results - Earnings Call Transcript
www.msn.com - May 11 at 3:41 AM
Genmabs (GNMSF) CEO Jan van de Winkel on Q4 2016 Results - Earnings Call TranscriptGenmab's (GNMSF) CEO Jan van de Winkel on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 22 at 10:48 PM
Genmab Lifts FY16 View For Revenue, Operating Income - Quick Facts - NasdaqGenmab Lifts FY16 View For Revenue, Operating Income - Quick Facts - Nasdaq
www.nasdaq.com - February 8 at 4:46 AM
Genmab Lifts FY16 View For Revenue, Operating Income - Quick FactsGenmab Lifts FY16 View For Revenue, Operating Income - Quick Facts
www.rttnews.com - February 6 at 5:33 PM
Genmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts - NasdaqGenmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts - Nasdaq
www.nasdaq.com - January 24 at 11:12 PM
Genmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick FactsGenmab Says 2016 Sales Of Darzalex Totaled $572 Mln - Quick Facts
www.rttnews.com - January 24 at 6:10 PM

SEC Filings

Genmab As (OTCMKTS:GNMSF) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Genmab As (OTCMKTS GNMSF) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.